Telix Pharmaceuticals Ltd (TLX) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Telix Pharmaceuticals Ltd  (NASDAQ: TLX)

Select the Financial Report: Select the Period:


Description of Telix Pharmaceuticals Ltd's Business Segments
Telix operates through five segments: Therapeutics (Tx), Precision Medicine (Px), International, MedTech, and Telix Manufacturing Solutions (TMS). Financial results are reported across three segments: Tx; Px, which includes International and MedTech; and TMS. The Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic oncology, and other solid tumors. Precision Medicine serves as the commercial division, delivering diagnostic imaging solutions and expanding geographically and by indication to support patient management and personalized therapies. MedTech focuses on advancing surgical solutions and digital products that complement Telix's precision medicines and therapeutics. The International segment manages commercial operations outside the U.S., covering EMEA, APAC, and Latin America. Telix Manufacturing Solutions operates a global network that delivers patient doses worldwide, investing in manufacturing capacity and technology to scale production, including next-generation alpha therapies. This infrastructure supports new product development and secures critical supplies for future cancer treatments. These segments represent distinct business activities and correspond with how the Managing Director and CEO monitors performance and allocates resources. Additional information is available in Note 3 of the Financial report.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.



Annual Report on Telix Pharmaceuticals Ltd Divisions, Sales by Country

 
Australia   Australia Segment contribution to total sales 0.16 % of total Revenue
Belgium   Belgium Segment contribution to total sales 0.07 % of total Revenue
Canada   Canada Segment contribution to total sales 0.32 % of total Revenue
United Kingdom   United Kingdom Segment contribution to total sales 0.07 % of total Revenue
United States   United States Segment contribution to total sales 64.24 % of total Revenue
Other Countries   Other Countries Segment contribution to total sales 2.05 % of total Revenue
At a Point in Time Precision Medicine   At a Point in Time Precision Medicine Segment contribution to total sales 98.5 % of total Revenue
Over Time Manufacturing Solutions   Over Time Manufacturing Solutions Segment contribution to total sales 0.35 % of total Revenue
segments   segments Segment contribution to total sales 66 % of total Revenue
Precision Medicine   Precision Medicine Segment contribution to total sales 64.97 % of total Revenue
Therapeutics   Therapeutics Segment contribution to total sales 0.8 % of total Revenue
Manufacturing Solutions   Manufacturing Solutions Segment contribution to total sales 0.23 % of total Revenue
China   China Segment contribution to total sales 0.05 % of total Revenue
Other countries   Other countries Segment contribution to total sales 1.71 % of total Revenue
At a point in time Precision Medicine   At a point in time Precision Medicine Segment contribution to total sales 64.96 % of total Revenue
Over time Precision Medicine   Over time Precision Medicine Segment contribution to total sales 0 % of total Revenue
Over time Manufacturing Solutions   Over time Manufacturing Solutions Segment contribution to total sales 0.23 % of total Revenue
Over time Therapeutics   Over time Therapeutics Segment contribution to total sales 0.8 % of total Revenue


Twelve months ended 2024
TLX s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Australia 1.22 0.16 %
Belgium 0.55 0.07 %
Canada 2.54 0.32 %
United Kingdom 0.58 0.07 %
United States 502.76 64.24 %
Other Countries 16.01 2.05 %
At a Point in Time Precision Medicine 770.94 98.5 %
Over Time Manufacturing Solutions 2.75 0.35 %
segments 516.55 66 %
Precision Medicine 508.51 64.97 %
Therapeutics 6.23 0.8 %
Manufacturing Solutions 1.82 0.23 %
China 0.38 0.05 %
Other countries 13.41 1.71 %
At a point in time Precision Medicine 508.40 64.96 %
Over time Precision Medicine 0.01 0 %
Over time Manufacturing Solutions 1.82 0.23 %
Over time Therapeutics 6.23 0.8 %
Total 782.68 100 %


Twelve months ended 2024
TLX s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
segments 336.16 65.08 %
Total 49.92 6.38 %

Twelve months ended 2024
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Australia 4.63 % -
Belgium 19.21 % -
Canada 99.84 % -
United Kingdom -55.67 % -
United States 2.68 % -
Other Countries 84.3 % -
At a Point in Time Precision Medicine 55.34 % -
Over Time Manufacturing Solutions 557.89 % -
Precision Medicine -34.05 % -
Therapeutics -33.42 % -
Manufacturing Solutions -33.93 % -
Summary of Revenues from External Customers by Product and Geographic Region ifrs-full RevenueAbstract - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.